Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Expected to Earn FY2023 Earnings of ($2.49) Per Share

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) – Stock analysts at Leerink Partnrs increased their FY2023 EPS estimates for Alnylam Pharmaceuticals in a research report issued on Monday, January 8th. Leerink Partnrs analyst M. Foroohar now anticipates that the biopharmaceutical company will post earnings of ($2.49) per share for the year, up from their prior […]

Related Keywords

William Blair ,Michaelw Bonney ,Leerink Partnrs ,Alnylam Pharmaceuticals Company Profile ,Nasdaq ,Alnylam Pharmaceutical ,Alnylam Pharmaceuticals ,Alnylam Pharmaceuticals Trading Down ,Capital Advisors Ltd ,News Ratings For Alnylam Pharmaceuticals Daily ,Kb Financial Partners ,Financial Gravity Asset Management Inc ,Institutional Investors Weigh In On Alnylam Pharmaceuticals ,V Square Quantitative Management ,Investment Management ,Needham Company ,Alnylam Pharmaceuticals Inc ,Free Report ,Get Free Report ,Pharmaceuticals Trading Down ,Gravity Asset Management ,Director Michael ,Alnylam Pharmaceuticals Daily ,Nasdaq Alny ,Dalny ,Medical ,02043q10 ,Earnings Estimates ,